<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079923</url>
  </required_header>
  <id_info>
    <org_study_id>09-007602</org_study_id>
    <nct_id>NCT01079923</nct_id>
  </id_info>
  <brief_title>Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation</brief_title>
  <official_title>Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research has shown that Vitamin D is important in preventing rickets in children,
      osteomalacia in adults, certain cancers, cardiovascular disease, Type 2 Diabetes, and
      metabolic syndrome. Data suggests that Vitamin D deficiency is common throughout the world.
      With increasing medical conditions being linked to Vitamin D deficiency, it is suggested that
      establishing early normal Vitamin D levels is important to long term health.

      There are low quantities of maternal Vitamin D that transfer from blood into breast milk.
      This places nursing infants at risk of developing low Vitamin D levels, and the American
      Academy of Pediatrics recommends they receive 400 international units (IU) of Vitamin D
      daily. If nursing mothers were supplemented with oral Vitamin D, this may produce adequate
      total Vitamin D in the breast milk for the growing infant to consume. By taking this
      potential therapeutic approach, this would prevent the burden of administering an oral
      Vitamin D liquid supplement to an infant.

      Recent laboratory technology now allows measurement of total Vitamin D (parent Vitamin D2
      plus parent Vitamin D3). The main objective of this pilot study is to compare total Vitamin D
      levels resulting from daily Vitamin D supplementation of 5,000 international units of
      cholecalciferol (Vitamin D3) orally for 28 days vs. 150,000 international units of
      cholecalciferol orally once in healthy, non-pregnant, non-lactating female subjects aged 18 �
      40. The research results will be used to help identify an optimal dosing regimen to
      administer to lactating mothers to hopefully deliver adequate total Vitamin D in nursing
      infants. This separate study will be conducted at a later date under a subsequent protocol.

      Previous research has demonstrated that Vitamin D3 levels become undetectable within 14 days
      after adult subjects received 100,000 international units of cholecalciferol. The
      investigators' central hypothesis is that daily dosing of 5,000 international units of
      cholecalciferol orally will maintain detectable total Vitamin D levels in serum after
      fourteen days, compared to high-dose 150,000 international units of oral cholecalciferol
      once.

      It is anticipated the aims of this pilot study will yield the following results. First, we,
      the investigators, hope to determine the resulting Vitamin D blood levels and calculate an
      appropriate dosing strategy for future research. Next we plan to measure the resulting
      25,hydroxyvitamin D levels that correspond with these dosing regimens, since
      25,hydroxyvitamin D is the major indicator of Vitamin D status in humans. Lastly, we will
      measure blood calcium and phosphorus levels to assure these doses of Vitamin D are tolerated
      by healthy female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D pharmacokinetics</measure>
    <time_frame>28 days</time_frame>
    <description>Characterize the differences in pharmacokinetics of oral Vitamin D3 between two dosing regimens within women of child-bearing age by evaluating any changes in the number of days of detectable total serum Vitamin D and area under the curve (AUC) above baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Supplementation Dosing Regimen</measure>
    <time_frame>28 days</time_frame>
    <description>Determine a Vitamin D3 dosing regimen that produces more days of detectable total serum Vitamin D to be used in an additional study examining the quantity of maternal vitamin D that crosses into breast milk for feeding infants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Supplementation Dosing Regimen Efficacy</measure>
    <time_frame>28 days</time_frame>
    <description>Assess differences in change in baseline 25-OH-D between two dosing regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Supplementation Safety</measure>
    <time_frame>28 days</time_frame>
    <description>Monitor for any adverse effects of Vitamin D supplementation, specifically hypercalcemia and hypophosphatemia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single High Dose Supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age 18 to 40 years, non-pregnant, non-lactating, female subjects .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily Dose Supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age 18 to 40 years, non-pregnant, non-lactating, female subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Single High Dose Cholecalciferol</intervention_name>
    <description>Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).</description>
    <arm_group_label>Single High Dose Supplementation</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Daily Dose Cholecalciferol</intervention_name>
    <description>Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).</description>
    <arm_group_label>Daily Dose Supplementation</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 40 years

          -  non-pregnant

          -  non-lactating

          -  female

          -  willing to participate in study with adequate compliance and follow-up

        Exclusion Criteria:

          -  Any clinically significant underlying chronic disease states (i.e. diabetes, asthma,
             seizure disorders, hypo/hyperthyroidism, hypercalcemia, hypophosphatemia, other
             endocrine disorders, absorption disorders)

          -  allergy to study medication or its components

          -  significant travel south of the 35° North latitude in the 28-day study period

          -  chronic use of steroids, anti-convulsants, or barbiturates

          -  participation in indoor tanning practices during the 28-day study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard R Lee, PharmD, BCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas D Thacher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael E Meekins, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004 Mar;79(3):362-71. Review. Erratum in: Am J Clin Nutr. 2004 May;79(5):890.</citation>
    <PMID>14985208</PMID>
  </reference>
  <reference>
    <citation>Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005 May;28(5):1228-30.</citation>
    <PMID>15855599</PMID>
  </reference>
  <reference>
    <citation>Foss YJ. Vitamin D deficiency is the cause of common obesity. Med Hypotheses. 2009 Mar;72(3):314-21. doi: 10.1016/j.mehy.2008.10.005. Epub 2008 Dec 2.</citation>
    <PMID>19054627</PMID>
  </reference>
  <reference>
    <citation>Suskind DL. Nutritional deficiencies during normal growth. Pediatr Clin North Am. 2009 Oct;56(5):1035-53. doi: 10.1016/j.pcl.2009.07.004. Review.</citation>
    <PMID>19931062</PMID>
  </reference>
  <reference>
    <citation>Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr. 2008 Jun;87(6):1738-42.</citation>
    <PMID>18541563</PMID>
  </reference>
  <reference>
    <citation>Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007 Jan;85(1):6-18. Review.</citation>
    <PMID>17209171</PMID>
  </reference>
  <reference>
    <citation>Mastaglia SR, Mautalen CA, Parisi MS, Oliveri B. Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women. Eur J Clin Nutr. 2006 May;60(5):681-7.</citation>
    <PMID>16391587</PMID>
  </reference>
  <reference>
    <citation>Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr. 2008 Mar;87(3):688-91.</citation>
    <PMID>18326608</PMID>
  </reference>
  <reference>
    <citation>Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003 Jan;77(1):204-10. Erratum in: Am J Clin Nutr. 2003 Nov;78(5):1047.</citation>
    <PMID>12499343</PMID>
  </reference>
  <reference>
    <citation>Thacher TD, Obadofin MO, O'Brien KO, Abrams SA. The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets. J Clin Endocrinol Metab. 2009 Sep;94(9):3314-21. doi: 10.1210/jc.2009-0018. Epub 2009 Jun 30.</citation>
    <PMID>19567516</PMID>
  </reference>
  <reference>
    <citation>Saadi HF, Dawodu A, Afandi B, Zayed R, Benedict S, Nagelkerke N, Hollis BW. Effect of combined maternal and infant vitamin D supplementation on vitamin D status of exclusively breastfed infants. Matern Child Nutr. 2009 Jan;5(1):25-32. doi: 10.1111/j.1740-8709.2008.00145.x.</citation>
    <PMID>19161542</PMID>
  </reference>
  <reference>
    <citation>Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004 Nov;89(11):5387-91.</citation>
    <PMID>15531486</PMID>
  </reference>
  <reference>
    <citation>Taylor SN, Wagner CL, Hollis BW. Vitamin D supplementation during lactation to support infant and mother. J Am Coll Nutr. 2008 Dec;27(6):690-701. Review.</citation>
    <PMID>19155428</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>November 16, 2012</last_update_submitted>
  <last_update_submitted_qc>November 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Bernard Lee, PharmD, BCPS</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>vitamin D3</keyword>
  <keyword>total vitamin D</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

